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Signs and Symptoms 
Hashimoto’s Disease: The Underactive Thyroid Disease 
Patty Anderson, RN, BSN 
Introduction 
     The thyroid gland is part of the 
endocrine system and has a 
widespread function that controls 
multiple organ systems and 
processes.  The main function of 
the thyroid gland is to produce 
and secrete two different thyroid 
hormones: triiodothyronine (T3) 
and thyroxine (T4), both of which 
help to meet the metabolic 
demands of the entire body.  
When the thyroid gland fails to 
produce T3/T4 hormones 
(primary gland failure) or is not 
activated successfully by the 
pituitary gland (by the release of 
thyroid stimulating hormone 
(TSH)), or hypothalamus, this 
results in low levels of circulating 
thyroid hormone.  As low levels of 
the circulating thyroid hormones 
continue, an overall slowing of the 
person’s metabolism occurs.  This 
underactive thyroid disease is 
called hypothyroidism (Chiasera, 
2013).    
     Although there are several 
causes for hypothyroidism, 
Hashimoto’s Thyroiditis (HT) is 
the most common cause of 
hypothyroidism in United States 
and is thought to be associated 
with genetic susceptibility and 
environmental factors.  HT is a 
chronic autoimmune disease and 
can present itself in an aggressive 
form or a mild form such as silent 
thyroiditis or postpartum 
thyroiditis leading to an 
undiagnosed hypothyroidism.  
Regardless of the virulence of the 
disease, HT can become serious if 
left untreated (Davies, 2015).    
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     HT is caused by an overt autoimmune 
response causing thyroid gland 
destruction.  Loss of immune tolerance 
(lack of regulatory T-cells) to normal 
thyroid cells leads to the production of 
antibodies directed against thyroid tissue, 
which causes destruction of the thyroid 
gland.  This destruction inhibits the release 
of thyroid hormones necessary for the 
metabolic processes.   
     The disease begins with an activated 
inflammatory process when an individual 
is genetically (familial) and 
environmentally (iodine diet, toxins, viral 
infect) predisposed for HT.  This 
inflammatory process initiates the 
accumulation of the human leukocyte 
antigen (HLA) Class II antigen-presenting 
cells (APC) into the thyroid gland.  HLA 
Class II is a set of molecules found on 
antigen-presenting cells such as dendritic 
cells and subclasses of macrophages.  HLAs 
present antigens from outside of the cell to 
T-lymphocytes.  This stimulates the 
multiplication of T-helper cells.  T-helper 
cells then stimulates B-cells to produce 
antibodies to the specific antigen.  When 
there is an accumulation of HLA Class II 
molecules in the thyroid gland, this causes 
damage to thyrocytes and causes the 
release of thyroid-specific proteins that are 
then seen on the cell surface of the encoded 
APC.  From here, the APC travels from the 
thyroid gland to the draining lymph nodes 
of the thyroid.  When the encoded APC 
interacts with the T-lymphocyte cells and 
B-lymphocyte cells in the draining lymph 
nodes, a production of thyroid 
autoantibodies occur against the thyroid 
antigens: thyroid peroxidase (TPO) and 
thyroglobulin (Tg).  Once the production of 
thyroid autoantibodies (anti-Tg antibodies 
and anti-thyroperoxidase antibodies) 
occurs, antigen-producing B-lymphocytes, 
T helper cells (CD4+), and cytotoxic T cells 
(CD+8), and macrophages infiltrate and 
accumulate in the thyroid gland through 
the formation, clonal expansion, and 
maturation of self-reactive T lymphocytes 
and B-lymphocytes in the lymph tissue of 
the thyroid gland.  This entire process of 
autoantibody, cytokine-mediated and 
apoptotic mechanisms of cytotoxicity leads 
to the destruction of the thyroid gland.  
This thyroid gland destruction inhibits the 
release of the thyroid hormones 
Triiodothyronine (T3) and Thyroxine (T4).  
This lack of hormone release leads to 
hypothyroidism and Hashimoto’s 
Thyroiditis (Davies, 2015).   
     Hashimoto’s thyroiditis is one of the most common 
autoimmune diseases in the United States.  The name 
of this disease was derived from the 1912 pathology 
report completed by Dr. Hakaru Hashimoto (Caturegli 
et al., 2013).  It is estimated that one in 300 persons in 
the United States has been diagnosed with some form 
of hypothyroidism and an estimated 13 million 
persons have hypothyroidism, but have not been 
properly diagnosed.  Hypothyroidism may not be 
present until later in life and affects women more than 
men.  Often times, hypothyroidism is ignored or 
misdiagnosed due to the multiple symptoms that 
appear similar to other diseases (Gaitonde, Rowley, & 
Sweeney, 2012).   
     Due to the widespread function of the thyroid gland, 
an untreated hypothyroidism can lead to multisystem 
complications including; cardiovascular diseases, 
pregnancy complications, and even life-threatening 
conditions.  An accurate diagnoses and treatment is 
critical.  Any form of hypothyroidism such as 
Hashimoto’s Thyroiditis is a serious disease and 
should be treated as such (Mendes, 2015).   
     Since the thyroid gland regulates the entire metabolism, the 
thyroid gland indirectly affects every cell, tissue, and organ in 
the body – from muscles, bones, and skin to the digestive 
tract, heart, and brain.  Since the thyroid gland is a 
multisystem functioning gland, there are a wide variety of 
signs and symptoms that may be present with Hashimoto’s 
disease and/or any form of hypothyroidism. Regardless of 
which type of hypothyroidism a person may have, the possible 
signs and symptoms will be the same.  Initially, 
hypothyroidism may present itself in a subclinical manner 
(mild and without symptoms), but as the disease progresses 
the symptoms become more apparent (NIH, 2013).     
     Signs and symptoms that can be seen in someone with a 
hypothyroid disease are: fatigue, constipation, dry skin, 
increased sensitivity to cold, muscle weakness, cramps or 
stiffness, coarse brittle thinning hair, brittle nails, hoarse 
voice, unintentional weight gain, depression, menstrual 
irregularities; heavy and excessive bleeding.  Physical exam 
findings that may also be seen are: bradycardia, goiter, 
diastolic hypertension, cognitive impairment, delayed deep 
tendon reflexes, edema, altered laboratory results: elevated 
TSH, decreased Free T4, normal or sometimes decreased Total 
or Free T3, hyperlipidemia, hyponatremia, and elevated 
creatine kinase, Hashimoto’s specific: Elevated serum 
concentrations of TPO autoantibodies (Ross, 2015).   
     In general, these symptoms are due to the decreased 
production of thyroid hormone.  Most of the symptoms are 
not manifested in the early stages of the disease, but as the 
disease progresses, the degree of the disease along with 
clinical manifestations will worsen.  When the metabolic rate 
drops to a critical level, a life threatening emergency known as 
“Myxedema Coma” can occur.  This event is characterized by 
hypothermia, hypoglycemia, severe bradycardia and altered 
level of consciousness (Hampton, 2013).  Proper diagnoses 
and treatment is life or death when dealing with 
hypothyroidism.   
     Since HT and hypothyroidism can present itself in a variety of 
ways and level of severity, the most important factor is an 
accurate recognition and diagnosis.  Diagnosing should always 
begin with a thorough physical exam and obtaining a complete 
medical history.  Taking time to interview the patient and truly 
hear what is being said is crucial.  In addition, focusing on one 
symptom will prevent a healthcare provider from accurately 
diagnosing someone with HT.  The healthcare provider needs to 
be well educated about hypothyroidism and its presenting 
symptoms.  Again, HT and/or hypothyroidism can easily be 
mistaken for other medical problems due the thyroid gland being 
a multisystem gland, which is why it is so important for healthcare 
providers to be well educated about this disease.     
     When the physical exam and medical history is complete and 
hypothyroidism or HT is suspected, diagnostic lab work must be 
obtained to confirm the diagnosis.  Lab work usually begins with a 
TSH level.  Normally, a TSH level above normal is indicative of 
hypothyroidism.  In addition, a T4 level should be obtained and 
will be lower than normal with hypothyroidism.  Although most 
persons with HT will eventually develop hypothyroidism due to 
the destruction of the thyroid gland, the TSH and T4 may present 
normally since hypothyroidism has not occurred at this time.  For 
a definitive diagnosis of HT, a person must test positive for serum 
antithyroid antibodies.  This test confirms the presence of 
autoantibodies that mistakenly attack the thyroid tissue.  A 
computerized tomography (CT) scan may also be performed to 
assess the thyroid gland for size, texture, nodules, and/or 
inflammation (NIH, 2013).  
     Treatment for HT depends upon goiter activity and/or if 
hypothyroidism is present.  If a person with HT does not have 
hypothyroidism and/or a goiter, continued monitoring should 
take place.  If a person with HT has a goiter but is still free of 
hypothyroidism, healthcare providers may treat the person in an 
effort to decrease the size of the goiter.  When a person with HT is 
positive for hypothyroidism, they must be treated with synthetic 
T4 (synthetic T4 stays in the body longer than synthetic T3).  The 
most common form of synthetic T4 that is currently being used is 
Synthroid.  Once Synthroid is initiated, healthcare providers must 
monitor the patient’s lab work closely to prevent the counter 
effect of hyperthyroidism.  Usually, lab work is rechecked every 3 
months after the initial start of Synthroid and/or if changes are 
being made to the patient’s Synthroid dosage (NIH, 2013).    
Finally, another very important nursing implications is patient 
education.  It is very important that a patient understands the 
disease, the importance of the treatment, and most importantly, 
compliance with taking medication as prescribed.  Noncompliance 
is not an option with HT.  Patient compliance is important in 
preventing extreme hypothyroidism such as Myxedema Coma.         
 
 
Nursing Implications 
Conclusion 
      In conclusion, HT is characterized by the loss of thyroid 
follicular cells, hypothyroidism, and the presence of 
autoantibodies against tissue-specific antigens such as thyroid 
peroxidase (TPO) and thyroglobulin (Tg).  The thyroid tissue is 
identified as having an infiltration of T cells and B cells which are 
reactive against the thyroid antigens.  The lymph system of the 
thyroid gland becomes involved and this leads to the death of the 
thyrocytes with the end result of hypothyroidism and Hashimoto’s 
Thyroiditis (Glick, Wodzinski, Fu, Levine, & Wald, 2013).      
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